CO6361900A2 - Composicion farmaceutica de un potente de hcv para su administración oral - Google Patents

Composicion farmaceutica de un potente de hcv para su administración oral

Info

Publication number
CO6361900A2
CO6361900A2 CO11063891A CO11063891A CO6361900A2 CO 6361900 A2 CO6361900 A2 CO 6361900A2 CO 11063891 A CO11063891 A CO 11063891A CO 11063891 A CO11063891 A CO 11063891A CO 6361900 A2 CO6361900 A2 CO 6361900A2
Authority
CO
Colombia
Prior art keywords
hcv
pharmaceutical composition
oral administration
powerful
pharmaceutically acceptable
Prior art date
Application number
CO11063891A
Other languages
English (en)
Inventor
Chen Feng Jing
Juan Francisco Gel
Maria Fernanda Villagra
Original Assignee
Boehringer Ingelheim Internat Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41650279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6361900(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Internat Gmbh filed Critical Boehringer Ingelheim Internat Gmbh
Publication of CO6361900A2 publication Critical patent/CO6361900A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica líquida del siguiente compuesto (1), un potente inhibidor viral de la hepatitis C (HCV), o su sal farmacéuticamente aceptable, para su administración oral:al menos un tensioactivo; y al menos un disolvente farmacéuticamente aceptable; y en el que la composición está sustancialmente libre de lípidos.
CO11063891A 2008-11-21 2011-05-24 Composicion farmaceutica de un potente de hcv para su administración oral CO6361900A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11678908P 2008-11-21 2008-11-21

Publications (1)

Publication Number Publication Date
CO6361900A2 true CO6361900A2 (es) 2012-01-20

Family

ID=41650279

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11063891A CO6361900A2 (es) 2008-11-21 2011-05-24 Composicion farmaceutica de un potente de hcv para su administración oral

Country Status (35)

Country Link
US (2) US20120101049A1 (es)
EP (1) EP2358355B1 (es)
JP (1) JP5553839B2 (es)
KR (1) KR20110087297A (es)
CN (1) CN102223875A (es)
AR (1) AR074391A1 (es)
AU (1) AU2009316755B2 (es)
BR (1) BRPI0921070A2 (es)
CA (1) CA2738732A1 (es)
CL (1) CL2011000878A1 (es)
CO (1) CO6361900A2 (es)
CY (1) CY1114892T1 (es)
DK (1) DK2358355T3 (es)
EA (1) EA022272B1 (es)
EC (1) ECSP11011065A (es)
ES (1) ES2445516T3 (es)
HR (1) HRP20140097T1 (es)
IL (1) IL211832A (es)
MA (1) MA32812B1 (es)
ME (1) ME01614B (es)
MX (1) MX2011005151A (es)
MY (1) MY155402A (es)
NZ (1) NZ592383A (es)
PE (1) PE20120032A1 (es)
PL (1) PL2358355T3 (es)
PT (1) PT2358355E (es)
RS (1) RS53121B (es)
SG (1) SG171771A1 (es)
SI (1) SI2358355T1 (es)
TN (1) TN2011000258A1 (es)
TW (1) TWI469801B (es)
UA (1) UA105777C2 (es)
UY (1) UY32252A (es)
WO (1) WO2010059667A1 (es)
ZA (1) ZA201102029B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
ME01718B (me) * 2009-07-07 2014-09-20 Boehringer Ingelheim Int Farmaceutska kompozicija za inhibitor proteaze virusnog Hepatitis C
MX2013003060A (es) 2010-09-30 2013-05-30 Boehringer Ingelheim Int Terapia de combinacion para tratar infeccion por hcv.
EA201390532A1 (ru) * 2010-10-08 2013-09-30 Новартис Аг Композиции сульфамидых ингибиторов ns3, содержащие витамин е
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
CN104244926A (zh) 2012-01-12 2014-12-24 勃林格殷格翰国际有限公司 作为强效的hcv 抑制剂的稳定的药物制剂
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
WO2013169577A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
SG11201507223TA (en) 2013-03-15 2015-10-29 Gilead Sciences Inc Macrocyclic and bicyclic inhibitors of hepatitis c virus
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2017062840A1 (en) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Combination therapy for the treatment of hepatitis c virus
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CA2466851C (en) * 2001-11-26 2012-09-11 Supergen, Inc. Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
UY28323A1 (es) * 2003-05-21 2004-12-31 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c
JP5156374B2 (ja) * 2004-05-25 2013-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 非環式ｈｃｖプロテアーゼインヒビターの調製方法

Also Published As

Publication number Publication date
ZA201102029B (en) 2011-11-30
IL211832A0 (en) 2011-06-30
EA022272B1 (ru) 2015-12-30
PT2358355E (pt) 2014-01-08
TW201023859A (en) 2010-07-01
KR20110087297A (ko) 2011-08-02
US20120101049A1 (en) 2012-04-26
US20150038532A1 (en) 2015-02-05
CY1114892T1 (el) 2016-12-14
AU2009316755B2 (en) 2015-10-08
ECSP11011065A (es) 2011-06-30
JP5553839B2 (ja) 2014-07-16
EP2358355A1 (en) 2011-08-24
SI2358355T1 (sl) 2014-02-28
MY155402A (en) 2015-10-15
TWI469801B (zh) 2015-01-21
JP2012509336A (ja) 2012-04-19
RS53121B (en) 2014-06-30
MA32812B1 (fr) 2011-11-01
ES2445516T3 (es) 2014-03-03
CN102223875A (zh) 2011-10-19
SG171771A1 (en) 2011-07-28
EP2358355B1 (en) 2013-11-06
PE20120032A1 (es) 2012-02-12
BRPI0921070A2 (pt) 2019-09-24
CA2738732A1 (en) 2010-05-27
UY32252A (es) 2010-06-30
AR074391A1 (es) 2011-01-12
DK2358355T3 (da) 2013-12-16
ME01614B (me) 2014-09-20
HRP20140097T1 (hr) 2014-03-14
IL211832A (en) 2015-02-26
NZ592383A (en) 2012-11-30
MX2011005151A (es) 2011-05-30
UA105777C2 (uk) 2014-06-25
AU2009316755A1 (en) 2010-05-27
EA201100795A1 (ru) 2012-01-30
WO2010059667A1 (en) 2010-05-27
PL2358355T3 (pl) 2014-04-30
CL2011000878A1 (es) 2011-09-02
TN2011000258A1 (en) 2012-12-17

Similar Documents

Publication Publication Date Title
CO6361900A2 (es) Composicion farmaceutica de un potente de hcv para su administración oral
CL2008003431A1 (es) Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih.
RS53209B (en) PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR
CL2008001005A1 (es) Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv.
AR089578A1 (es) Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion
CL2012000919A1 (es) Composicion que comprende un compuesto derivado de metoxicarbonil-amino-metilbutanoil-pirrolidinil-imidazol de formula i, inhibidor especifico de ns5a de hcv, y un compuesto derivado de oxo-pirrolidin-quinoleina de formula ii, inhibidor de proteasa ns3 de hcv; y uso en el tratamiento de la hepatitis c.
UY32717A (es) Inhibidores de la replicación de virus de la gripe
CL2011002643A1 (es) Composicion farmaceutica que comprende r7227, ritonavir y un excipiente farmaceuticamente aceptable; kit para el tratamiento del virus de la hepatitis c.
ECSP099601A (es) Inhibidores de proteasa de serina
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
CL2012000573A1 (es) Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
UY29266A1 (es) Compuestos de piridazinona
ECSP045223A (es) Composiciones farmacéuticas para inhibidores de proteasa viral de la hepatitis c
AR049274A1 (es) Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
CO6351741A2 (es) Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
ECSP077412A (es) Derivados de indol tetracíclicos como agentes antivíricos
WO2010068760A3 (en) New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
CL2011000136A1 (es) Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c.
CL2007003540A1 (es) Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
ES2572001T3 (es) Derivado de bisfurano antivírico como inhibidor de la proteasa del VIH e intermedios del mismo
BR112013028487A2 (pt) inibidores do vírus da hepatite c
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.

Legal Events

Date Code Title Description
FC Application refused